This trial is evaluating whether ALLO-605 will improve 3 primary outcomes in patients with Neoplasms, Plasma Cell. Measurement will happen over the course of 28 days.
This trial requires 136 total participants across 1 different treatment group
This trial involves a single treatment. ALLO-605 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"The most common side effect was fatigue, which occurred in almost half of participants treated with allo-605. Other common side effects included nausea and vomiting, diarrhea, headache, constipation, dry mouth, itchiness, rash, itching, insomnia, joint tenderness, abdominal pain, dyspepsia, dizziness, chest discomfort, anxiety, depression, shortness of breath, cough, muscle aches, weakness, and fever." - Anonymous Online Contributor
"At least one case of MM should occur in about 1.5 cases per 100,000 US population each year. In all, at least 3 cases of MM occurred per 100,000 US population for every year between 2001 and 2010. The incidence and prevalence rates appear to be increasing, likely because of improved survival and increased exposure to exposures such as ionizing radiation and environmental toxins." - Anonymous Online Contributor
"Though the safety profile for allo-605 appears similar to what has been seen with other agents used to treat multiple myeloma, the low rate of serious adverse events warrants further investigation." - Anonymous Online Contributor
"The 5 year survival rate was 24%, which is surprisingly low when compared to other cancers. Since the disease has a long latency period, it is important to detect and treat myeloma early." - Anonymous Online Contributor
"Allo-605 selectively targets ALK+ MM cells but not ALK- MM cells. This suggests that allo-605 may be a useful tool in the treatment of ALK+ MM." - Anonymous Online Contributor
"There is an increased risk for the development of cardiovascular disease in MM patients as compared to the general population, especially in those treated with bortezomib. It is therefore essential to oversee the patient's cardiovascular status during and after treatment with this drug. Further research is needed to understand the mechanisms involved in this association." - Anonymous Online Contributor
"Allo-605 is a promising anticancer agent and deserves further investigation. It would not be suitable for broad application on multiple myeloma patients because of its low therapeutic index." - Anonymous Online Contributor
"Results from a recent paper presented here suggest that MM in remission can have a potentially favorable outcome if it were to remain in remission." - Anonymous Online Contributor
"We conclude that (1) genetic factors play an important role in the etiology of multiple myeloma; (2) the occurrence of the disease does not follow a Mendelian pattern of inheritance; and (3) familial aggregation results from environmental influences outside of the family." - Anonymous Online Contributor
"The majority of patients with multiple myeloma were diagnosed with an underlying plasma cell neoplasm (meaning they had one of the plasma cell tumors). Secondary multiple myeloma was more common than primary multiple myeloma." - Anonymous Online Contributor
"The average age at diagnosis was 64 years (range 53-85 years), with 45% diagnosed before the age of 70 years. There were no differences in survival based on gender, race, stage of disease, and number of bone lesions." - Anonymous Online Contributor